Reckitt Benckiser Announces Proposed $16.7 Billion Acquisition of Mead Johnson

February 3 News: Reckitt, the parent company of Durex, plans to acquire U.S. baby food manufacturer Mead Johnson for $16.7 billion (approximately RMB 144.562 billion). If completed, this transaction would become Reckitt’s largest acquisition in its history.

Reckitt is a British fast-moving consumer goods company specializing in health, hygiene, and home care. Founded in 1823, it owns brands such as Durex, Scholl, Dettol, and Veet. The company operates in more than 60 countries and regions worldwide, with its global headquarters in London, UK, and regional headquarters in Singapore, Dubai, and Amsterdam. In 2010, Reckitt completed the acquisition of SSL International, the manufacturer of Durex, for $3.2 billion.

Mead Johnson is a U.S.-based manufacturer of infant and young child nutrition products. As the world’s third-largest baby food manufacturer, it holds approximately 10% of the global baby food market, trailing only Nestlé and Danone.

Regarding this transaction, Mead Johnson stated in its announcement that it is in negotiations with Reckitt Benckiser to sell its shares at $90 per share (representing a 29.5% premium over the closing price on the day prior to the disclosure of Reckitt Benckiser’s acquisition plans). Reckitt Benckiser indicated that the total valuation of Mead Johnson stands at $16.7 billion, with the acquisition to be financed through a combination of cash and debt.

Both parties are currently conducting due diligence and discussing transaction details. Reckitt Benckiser and Mead Johnson stated in their respective announcements that no substantive agreement has been reached yet, and there is no guarantee that the final transaction will be completed.

In fact, the completion of this transaction could bring new breakthroughs to the businesses of both parties involved, especially for Mead Johnson. Due to the fierce competition in the infant food market, its business has been declining continuously in recent years, and there have been multiple rumors about it being acquired.

Financial reports show that Mead Johnson’s revenue for fiscal year 2016 was $3.743 billion, a decrease of 8.07% compared to 2015; net profit was $545 million, down 16.62% from 2015. In 2015, these two key business metrics also declined year-over-year, by 7.67% and 9.21%, respectively. Geographically, Mead Johnson experienced varying degrees of decline in its major markets: Asia, North America, and Latin America. The Asian market, which accounts for more than half of its revenue, saw a significant drop of 9%. Mead Johnson had previously stated that the primary reason for the decline in performance was intense competition in the infant formula market. Additionally, changes in consumer structure and distribution channels contributed to the failure of its market strategy.

Since last year, Mead Johnson has been the subject of recurring merger and acquisition rumors with other infant food manufacturers, with potential acquirers including Danone and Nestlé. Subsequently, Danone acquired WhiteWave, a soy milk manufacturer, while Nestlé acquired Pfizer’s infant nutrition business.

Beyond Durex’s impressive performance, Reckitt has faced challenges in other sectors. Taking the Chinese market as an example, Reckitt intensified its expansion in China around 2012 by establishing its North Asia headquarters in Beijing. The company adopted a product portfolio centered on health, hygiene, and home care, planning to roll out a range of brands including Dettol, Veet, Finish, Air Wick, Harpic, Durex, and Scholl. However, this “broad and comprehensive” strategy proved ill-suited to the Chinese market, and its operations in China did not achieve success. In the daily chemicals segment, Reckitt still lags behind earlier entrants such as Procter & Gamble and Unilever.

Subsequently, Reckitt began to adjust its product strategy, gradually shifting its business focus back to condom operations led by Durex and its pharmaceutical business, acquiring Anhui Guilong, a traditional Chinese medicine enterprise, as well as certain businesses from foreign pharmaceutical companies.

This round of mergers and acquisitions also demonstrates a differentiated strategic move in its global competition with peers.

In response, analysts believe that while Mead Johnson’s consecutive years of declining performance make it less than an ideal target, Reckitt may need to find new breakthroughs in its differentiated competition with rivals such as Unilever and Procter & Gamble, making infant formula manufacturers a potentially favorable option.

According to data from Borei Consulting, the global market size for infant formula is projected to reach $80 billion. Accordingly, the acquisition of Mead Johnson enables Reckitt Benckiser to enter the more profitable and relatively mature maternal and child health market, thereby enhancing its product relevance in the fertility and maternal-child sectors.

Globally, the market for infant formula is also on an upward trend. Factors such as China’s two-child policy and the increasing participation of women in the workforce across Southeast Asian countries are driving up demand for formula milk.

The aforementioned analysts also stated that if the current round of transactions is completed, how Reckitt and Mead Johnson will cooperate will be the biggest highlight. Whether to maintain the independence of Mead Johnson's business framework and financial reports, as well as the integration of both parties at the brand and business levels, are tests that should be addressed.

The market appeared highly confident in the partnership between the two parties. Following the announcement, Reckitt Benckiser’s stock rose by 4%, while Mead Johnson’s share price surged by as much as 24%. However, as of February 4, both companies’ stock prices had eased back slightly.